Theresa Heggie, Director at BIOCRYST PHARMACEUTICALS INC (BCRX), sold 6,698 shares at $6.11 ($41K) on 2024-06-14, disclosed to the SEC on 2024-06-14.
Seasonal sale ($41k) by Director — this insider has traded BCRX in June in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| BCRX | BUY | 2019-11-18 | $7K | — | Filing → |